Download PDF
Thromb Haemost 2013; 109(03): 479-487
DOI: 10.1160/TH12-08-0604
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Acquired factor XIII deficiency: a therapeutic challenge

Françoise Boehlen
1   Angiology and Haemostasis Division, University Hospitals and School of Medicine, Geneva, Switzerland
,
Alessandro Casini
1   Angiology and Haemostasis Division, University Hospitals and School of Medicine, Geneva, Switzerland
,
Carlo Chizzolini
2   Immunology& Allergy, University Hospitals and School of Medicine, Geneva, Switzerland
,
Behrouz Mansouri
3   Division of Transfusion Medicine, University Hospital, Bern, Switzerland
,
Hans Peter Kohler
4   Laboratory for Haemostasis Research, Department of Haematology, University Hospital of Bern and Department of Internal Medicine, Spital Netz Bern Hospitals, Bern, Switzerland
,
Verena Schroeder
4   Laboratory for Haemostasis Research, Department of Haematology, University Hospital of Bern and Department of Internal Medicine, Spital Netz Bern Hospitals, Bern, Switzerland
,
Guido Reber
1   Angiology and Haemostasis Division, University Hospitals and School of Medicine, Geneva, Switzerland
,
Philippe de Moerloose
1   Angiology and Haemostasis Division, University Hospitals and School of Medicine, Geneva, Switzerland
› Author Affiliations
Further Information

Publication History

Received: 23 August 2012

Accepted after major revision: 07 January 2012

Publication Date:
29 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

Less than 60 cases of acquired factor (F)XIII deficiencies have been reported, most having distinct clinical features. To illustrate the therapeutic challenges of acquired FXIII inhibitors, we report a case of a 65-year-old patient with no previous bleeding history who suddenly developed massive haemorrhages associated to a strong and isolated FXIII inhibitor. No underlying disorder has been detected till now after three years of follow-up. Despite aggressive treatment with prednisone, rituximab, cyclophosphamide, immunoglobulin, immunoadsorption and immune tolerance his inhibitor is still present, although at low titre and with a clinical benefit since the patient has no more bleed since more than one year. Moreover the patient had a venous thromboembolic complication. After a review of the management of acquired FXIII deficiency patients and based on the management of acquired haemophilia we discuss a possible strategy for such difficult cases.

Keywords

Acquired factor XIII deficiency - factor XIII concentrates - thrombosis - immunosuppression - Fibrogammin P®
 

  • References

  • 1 Ichinose A, Souri M. As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011; 105: 925-927.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Kohler HP, Ichinose A, Seitz R. et al., on behalf of the Factor XIII and Fibrinogen SSc Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9: 1404-1406.
    CrossrefPubMedGoogle Scholar
  • 3 Karimi M, Bereczky Z, Cohan N. et al. Factor XIII Deficiency. Semin Thromb Hemost 2009; 35: 426-438.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Ajzner E, Schlammadinger A, Kerenyi A. et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009; 113: 723-725.
    CrossrefPubMedGoogle Scholar
  • 5 Lorand L, Maldonado N, Fradera J. et al. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol 1972; 23: 17-27.
    CrossrefPubMedGoogle Scholar
  • 6 McDevitt NB, McDonagh J, Taylor HL, Roberts HR. An acquired inhibitor to factor XIII. Arch Intern Med 1972; 130: 772-777.
    CrossrefPubMedGoogle Scholar
  • 7 Lopaciuk S, Bykowska K, McDonagh JM. et al. Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest 1978; 61: 1196-1203.
    CrossrefPubMedGoogle Scholar
  • 8 Tosetto A, Castaman G, Rodeghiero F. Acquired plasma factor XIII deficiencies. Haematologica 1993; 78 (Suppl. 02) 5-10.
    PubMedGoogle Scholar
  • 9 Nijenhuis AV, van Bergeijk L, Huijgens PC. et al. Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature. Haematologica 2004; 89: ECR14.
    PubMedGoogle Scholar
  • 10 Luo YY, Zhang GS. Acquired factor XIII inhibitor: clinical features, treatment, fibrin structure and epitope determination. Haemophilia 2011; 17: 393-398.
    CrossrefPubMedGoogle Scholar
  • 11 Miesbach W. Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Thromb Haemost 2005; 93: 1001-1003.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Ishida F, Okubo K, Ito T. et al. Spontaneous regression of the inhibitor against the coagulation factor XIII A subunit in acquired factor XIII deficiency. Thromb Haemost 2010; 104: 1284-1285.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Gailani D. An IgG inhibitor against coagulation factor XIII: resolution of bleeding after plasma immunoadsorption with staphylococcal protein A. Am J Med 1992; 92: 110-112.
    CrossrefPubMedGoogle Scholar
  • 14 Gregory TF, Cooper B. Case report of an acquired factor XIII inhibitor: diagnosis and management. Proc Bayl Univ Med Cent 2006; 19: 221-223.
    CrossrefPubMedGoogle Scholar
  • 15 Lorand L, Velasco PT, Rinne JR. et al. Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system. Proc Natl Acad Sci USA 1988; 85: 232-236.
    CrossrefPubMedGoogle Scholar
  • 16 Nakamura S, Kato A, Sakata Y. et al. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988; 68: 313-319.
    CrossrefPubMedGoogle Scholar
  • 17 Karoui M, Bel Haj AZ, Othman BT. et al. Acquired factor XIII deficiency and chronic myeloid splenomegaly. Tunis Med 1989; 67: 57-60.
    PubMedGoogle Scholar
  • 18 Daly HM, Carson PJ, Smith JK. Intracerebral haemorrhage due to acquired factor XIII inhibitor--successful response to factor XIII concentrate. Blood Coagul Fibrinolysis 1991; 2: 507-514.
    CrossrefPubMedGoogle Scholar
  • 19 Krumdieck R, Shaw DR, Huang ST. et al. Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenstrom’s macroglobulinemia. Am J Med 1991; 90: 639-645.
    PubMedGoogle Scholar
  • 20 Fukue H, Anderson K, McPhedran P. et al. A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA. Blood 1992; 79: 65-74.
    PubMedGoogle Scholar
  • 21 Donnet A, Trefouret S, Alessi MC. et al. Intradural hematoma of the foramen magnum associated with factor XIII deficiency. Rev Neurol 1994; 150: 164-166.
    PubMedGoogle Scholar
  • 22 Tosetto A, Rodeghiero F, Gatto E. et al. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol 1995; 48: 34-39.
    CrossrefPubMedGoogle Scholar
  • 23 Ahmad F, Solymoss S, Poon MC. et al. Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus. Br J Haematol 1996; 93: 700-703.
    CrossrefPubMedGoogle Scholar
  • 24 Lorand L, Velasco PT, Murthy SN. et al. Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood 1999; 93: 909-917.
    CrossrefPubMedGoogle Scholar
  • 25 Hayashi T, Kadohira Y, Morishita E. et al. A case of acquired FXIII deficiency with severe bleeding symptoms. Haemophilia 2012; 18: 618-620.
    CrossrefPubMedGoogle Scholar
  • 26 Ariens RA, Kohler HP, Mansfield MW. et al. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol 1999; 19: 2012-2016.
    CrossrefPubMedGoogle Scholar
  • 27 Katona E, Haramura G, Karpati L. et al. A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thromb Haemost 2000; 83: 268-273.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Kohler HP, Ariens RA, Whitaker P. et al. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. Thromb Haemost 1998; 80: 704.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Reynolds TC, Butine MD, Visich JE. et al. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers. J Thromb Haemost 2005; 3: 922-928.
    CrossrefPubMedGoogle Scholar
  • 30 Inbal A, Oldenburg J, Carcao M. et al. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012; 119: 5111-5117.
    CrossrefPubMedGoogle Scholar
  • 31 Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol 1998; 5: 372-375.
    CrossrefPubMedGoogle Scholar
  • 32 Collins P, Baudo F, Huth-Kuhne A. et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010; 3: 161.
    CrossrefPubMedGoogle Scholar
  • 33 Delgado J, Jimenez-Yuste V, Hernandez-Navarro F. et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
    CrossrefPubMedGoogle Scholar
  • 34 Muszbek L, Bagoly Z, Bereczky Z. et al. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008; 6: 190-205.
    CrossrefPubMedGoogle Scholar
  • 35 Girolami A, Ruzzon E, Tezza F. et al. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia 2006; 12: 345-351.
    CrossrefPubMedGoogle Scholar
  • 36 Almeida A, Khair K, Hann I, Liesner R. Unusual presentation of factor XIII deficiency. Haemophilia 2002; 8: 703-705.
    CrossrefPubMedGoogle Scholar
  • 37 Lim W, Moffat K, Hayward CP. Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency. J Thromb Haemost 2004; 2: 1017-1019.
    CrossrefPubMedGoogle Scholar
  • 38 Huth-Kuhne A, Baudo F, Collins P. et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566-575.
    CrossrefPubMedGoogle Scholar
  • 39 Hay CR, Brown S, Collins PW. et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
    CrossrefPubMedGoogle Scholar
  • 40 Shetty S, Bhave M, Ghosh K. Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options. Autoimmun Rev 2011; 10: 311-316.
    CrossrefPubMedGoogle Scholar
  • 41 Collins PW. Management of acquired haemophilia A. J Thromb Haemost 2011; 9 (Suppl. 01) 226-235.
    PubMedGoogle Scholar
  • 42 Coppola A, Favaloro EJ, Tufano A. et al. Acquired inhibitors of coagulation factors: part I-acquired hemophilia a. Semin Thromb Hemost 2012; 38: 433-446.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Sborov DW, Rodgers GM. Acquired hemophilia a: a current review of autoantibody disease. Clin Adv Hematol Oncol 2012; 10: 19-27.
    PubMedGoogle Scholar
  • 44 Stasi R, Brunetti M, Stipa E. et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-4428.
    CrossrefPubMedGoogle Scholar
  • 45 Wiestner A, Cho HJ, Asch AS. et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-3428.
    CrossrefPubMedGoogle Scholar
  • 46 Onitilo AA, Skorupa A, Lal A. et al. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost 2006; 96: 84-87.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112: 250-255.
    CrossrefPubMedGoogle Scholar
  • 48 Collins P, Baudo F, Knoebl P. et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120: 47-55.
    CrossrefPubMedGoogle Scholar
  • 49 Castaman G, Tosetto A. Is a reduced intensity treatment with Rituximab effective in acquired haemophilia A?. Haemophilia 2011; 17: 817-818.
    PubMedGoogle Scholar
  • 50 Eisert S, Mosler K, Laws HJ. et al. Successful use of mycophenolate mofetil and prednisone in a 14-year-old girl with acquired hemophilia A. Thromb Haemost 2005; 93: 792-793.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Lewis JH, Szeto IL, Ellis LD. et al. An acquired inhibitor to coagulation factor 13. Johns Hopkins Med J 1967; 120: 401-407.
    PubMedGoogle Scholar
  • 52 Godal HC. An inhibitor to fibrin stabilizing factor (FSF, factor XIII). Scand J Haematol 1970; 7: 43-48.
    CrossrefPubMedGoogle Scholar
  • 53 Otis PT, Feinstein DI, Rapaport SI. et al. An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood 1974; 44: 771-781.
    PubMedGoogle Scholar
  • 54 Milner GR, Holt PJ, Bottomley J. et al. Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII. J Clin Pathol 1977; 30: 770-773.
    CrossrefPubMedGoogle Scholar
  • 55 Shires L, Gomperts ED, Bradlow BA. An acquired inhibitor to factor XIII A case report. S Afr Med J 1979; 56: 70-72.
    PubMedGoogle Scholar
  • 56 Petri M, Ellman L, Carey R. Acquired factor XIII deficiency with chronic myelomonocytic leukemia. Ann Intern Med 1983; 99: 638-639.
    CrossrefPubMedGoogle Scholar
  • 57 Fear JD, Miloszewski KJ, Losowsky MS. An acquired inhibitor of factor XIII with a qualitative abnormality of fibrin cross-linking. Acta Haematol 1984; 71: 304-309.
    CrossrefPubMedGoogle Scholar
  • 58 Standen G, Birchall J, Morse C. et al. A large bruise. Lancet 1999; 353: 1934.
    CrossrefPubMedGoogle Scholar
  • 59 Lorand L, Velasco PT, Hill JM. et al. Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against actor XIII. Thromb Haemost 2002; 88: 919-923.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Luo Y, Zhang G, Zuo W. et al. Acquired factor XIII inhibitor in monoclonal gammopathy of undetermined significance: characterization and cross-linked fibrin ultrastructure. Ann Hematol 2010; 89: 833-834.
    CrossrefPubMedGoogle Scholar